Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP1LC3B | Q9GZQ8 | 3/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.35 |
| ▸ | FURIN | P09958 | 3/20 | 0.35 |
| ▸ | HRH1 | P35367 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NMT2 | O60551 | 1/20 | 0.33 |
| ▸ | NMT1 | P30419 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22068492 | 0.94 | MAP1LC3B (0.36) | MAP1LC3BKLKB1FURINHRH1KMT2A | |
| SCHEMBL29284586 | 0.85 | NPC1 (0.41) | MAP1LC3BKMT2AMEN1HTT | |
| SCHEMBL22068550 | 0.84 | MAP1LC3B (0.37) | MAP1LC3BKLKB1FURINHRH1KMT2A | |
| SCHEMBL22068464 | 0.81 | KLKB1 (0.38) | MAP1LC3BKLKB1FURINHRH1NMT2 | |
| SCHEMBL29284569 | 0.80 | NPC1 (0.41) | MAP1LC3BKMT2AMEN1HTT | |
| SCHEMBL29284547 | 0.80 | NPC1 (0.41) | MAP1LC3BKMT2AMEN1HTT | |
| SCHEMBL22068098 | 0.79 | NPC1 (0.40) | MAP1LC3BKMT2AMEN1HTT | |
| SCHEMBL22068547 | 0.79 | MAP1LC3B (0.36) | MAP1LC3BKLKB1FURINHRH1FAP | |
| SCHEMBL17987754 | 0.79 | MAP1LC3B (0.37) | MAP1LC3BKLKB1FURINHRH1KMT2A | |
| SCHEMBL22068096 | 0.78 | NPC1 (0.41) | MAP1LC3BKMT2AMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11207420-B2 | Cytotoxin and conjugate, uses of same and preparation method therefor | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-12-28 | — | — | US | disclosed |
| US-20200179529-A1 | CYTOTOXIN AND CONJUGATE, USES OF SAME AND PREPARATION METHOD THEREFOR | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11207420-B2 | Cytotoxin and conjugate, uses of same and preparation method therefor | CD2, HAVCR2, CD4 | MAP1LC3B 1411/4885KLKB1 408/4885FURIN 676/4885 |
| US-20200179529-A1 | CYTOTOXIN AND CONJUGATE, USES OF SAME AND PREPARATION METHOD THEREFOR | CD2, HAVCR2, CD4 | MAP1LC3B 1411/4885KLKB1 408/4885FURIN 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.